Share on StockTwits

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $133.15, for a total value of $665,750.00. Following the completion of the sale, the chief executive officer now directly owns 579,023 shares of the company’s stock, valued at approximately $77,096,912. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 8.81% during mid-day trading on Wednesday, hitting $144.23. 2,021,895 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 1-year low of $77.25 and a 1-year high of $176.60. The stock’s 50-day moving average is $145. and its 200-day moving average is $144.8. The company has a market cap of $8.686 billion and a P/E ratio of 97.97.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Tuesday, August 5th. The company reported $2.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the prior year, the company posted $1.43 earnings per share. The company’s quarterly revenue was up 39.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.18 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, August 7th. They now have a $150.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday, August 6th. Finally, analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday, August 6th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $174.05.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.